Published in Hepatitis Weekly, March 19th, 2001
Physicians frequently look for viral clearance at the end of therapy to determine sustained response after interferon (IFN) monotherapy or interferon/ribavirin combination therapy for HCV patients. However, the best determinant for predicting sustained response to either therapy, according to researchers at the University of Alcala de Henares School of Medicine in Spain, is to measure viral levels at patient-specific time intervals.
J.L. Calleja and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.